Gilead signs hepatitis C pact to cut drug cost for poor

U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations.

http://in.reuters.com/article/2014/09/15/us-gilead-sciences-india-idINKBN0HA0TT20140915

YOU ARE BEING REDIRECTED TO THE ARTICLE
. . .
× CLOSE

PROCESSING